MarketScreener reports on analyst ratings and price targets for Johnson & Johnson.
3 reports, 2 independent
Updated Oct 12
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketScreener reports on analyst ratings and price targets for Johnson & Johnson.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Divan raised the price target on Johnson & Johnson stock.Sub-event
MarketScreener reports on JNJ analyst ratings.1 source
Keep exploring
The entities involved
-
MarketScreener
Online media for stock market investors
Nothing else this week.
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
Related events
- Institutional investors boosted their stake in Johnson & Johnson (JNJ) shares, highlighting the company's drug profits and balance sheet in filings with the SEC.
- Analyst targets are being lowered amid new entrants challenging market dominance for medical technology companies.
- A fund trimmed its position in Johnson & Johnson (JNJ) stock and disclosed the transaction via financial filings with the SEC.
- Johnson & Johnson and Bank of America Merrill Lynch participated in the Q3 earnings season on October 7, 2026.
- Johnson & Johnson successfully spun off Kenvue to focus on core business, while FED policy signals affect market perception of JNJ.